Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Daratumumab in mild to moderate Alzheimer's disease
NCT04070378Phase 2Completed
- Sponsor
- Marc L. Gordon, M.D.
- Start
- Nov 2019
- Primary completion
- Jun 2023
- Modality
- Recombinant Proteins and Enzymes, Monoclonal Antibodies
- Countries
- 1
01
Overview
A Phase 2 trial of daratumumab in Alzheimer's disease (AD), sponsored by Marc L. Gordon, M.D.. Started Nov 2019; status: completed.
02
Drugs
daratumumab
03
Conditions
Alzheimer's disease (AD)
Beyond the preview
Go deeper on NCT04070378.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04070378.